Last Week in Biomedicine | June 14–20 | Part 2 of 2: Mezigdomide Myeloma, HCM Heart Drug

Part 2 of our week of June 14–20, 2026 wrap-up covers a new molecular glue for relapsed multiple myeloma that cut disease progression by half, a heart drug that may finally work forboth forms of hypertrophic cardiomyopathy, and a new combination regimen poised to upgrade the first-line standard of care in myelofibrosis.
In Part 2 we cover:4. Bristol Myers Squibb — Mezigdomide for relapsed/refractory multiple myeloma (Phase 3)
5. Edgewise Therapeutics — EDG-7500 for obstructive and non-obstructive hypertrophic cardiomyopathy (Phase 2)
6. Karyopharm Therapeutics / Menarini — Selinexor plus ruxolitinib for first-line myelofibrosis (Phase 3)
The most patient-impactful of these three is probably the Edgewise heart drug. Hypertrophic cardiomyopathy — a too-thick heart muscle that makes it hard to pump blood — is the most common inherited heart disease, but today'smyosin-inhibitor drugs only help people whose blood flow is physically blocked. EDG-7500 showed clear improvements in both the obstructive and non-obstructive forms, potentially more than doubling the number of patients who could benefit.
Catch Part 1 if you missed it. Subscribe at TrialBreaks.com.
#biomedicine #clinicaltrials #science #oncology #cardiology #hematology#myeloma #HCM #cardiomyopathy #myelofibrosis #CELMoD #sarcomere#drugdevelopment #precisionmedicine